[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614778":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":26,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":26},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuronavigation-Guided Low-Frequency rTMS","EXPERIMENTAL","Participants in this arm receive low-frequency rTMS where the coil positioning is guided and recorded by a neuronavigational system during each of the 10 sessions. The system ensures precise targeting of the M1 hotspot contralateral to the lesion.",[13],"Device: Neuronavigation-Assisted rTMS for Stroke Hemiparesis",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional Positioning Low-Frequency rTMS","ACTIVE_COMPARATOR","Participants in this arm receive the same low-frequency rTMS, but the coil positioning is performed via Standard Manual Localization (e.g., using cap positioning) over the M1 hotspot.",[19],"Device: Standard Localization rTMS for Stroke Hemiparesis",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Neuronavigation-Assisted rTMS for Stroke Hemiparesis","Low-frequency (1 Hz) rTMS targeting the M1 \"hotspot\" contralateral to the lesion, delivered at 80% motor threshold (MT). Each session consists of 1,200 pulses (10 seconds ON, 1 second OFF, repeated 120 cycles). Treatment schedule: 1 session daily, 5 days\u002Fweek, for 2 consecutive weeks (10 sessions total). Coil positioning is guided by a neuronavigational system using infrared camera and tracking balls.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard Localization rTMS for Stroke Hemiparesis","Low-frequency (1 Hz) rTMS targeting the M1 \"hotspot\" contralateral to the lesion, delivered at 80% MT. Each session consists of 1,200 pulses (10 seconds ON, 1 second OFF, repeated 120 cycles). Treatment schedule: 1 session daily, 5 days\u002Fweek, for 2 consecutive weeks (10 sessions total). Coil positioning is performed using standard manual localization with cap positioning.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Ting-Chun Fang, M.D.","CONTACT","+886-965020216","immotalman@hotmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Ting-Chun Fang","Attending Physician","100614778","the-impact-of-neuronavigation-in-rtms-for-hemiplegic-stroke-patients-100614778",false,"NCT07284017","The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients.","The Impact of Neuronavigation in Repetitive Transcranial Magnetic Stimulation (rTMS) for Hemiplegic Stroke Patients.","NeurorTMS-HS","Inclusion Criteria:\n\n* First-ever ischemic or hemorrhagic stroke confirmed by imaging.\n* Stroke causing unilateral upper limb weakness (MRC grade \\\u003C=3)\n* Stroke onset must be between 2 weeks and 6 months prior to enrollment (subacute phase).\n* Age between 20 and 85 years old.\n* Stable vital signs, clear consciousness, and no cognitive impairment.\n* Able to cooperate with assessments and treatment.\n* Written informed consent must be signed by the patient or a legal guardian.\n\nExclusion Criteria:\n\n* Contraindications to TMS (e.g., metallic implants in head, pacemaker, cochlear implant).\n* History of epilepsy or seizures.\n* Pregnancy.\n* Severe cognitive or communication disorders, or inability to give informed consent.\n* Unstable medical conditions affecting participation.\n* Use of certain medications, including benzodiazepines, antidepressants, muscle relaxants (baclofen, tizanidine), or ongoing botulinum toxin injections for post-stroke spasticity.\n* Modified Rankin Scale (mRS) score \\>=5 .","ALL","20 Years","85 Years",{"count":53,"type":54},30,"ESTIMATED","INTERVENTIONAL",[57],"NA","This is a randomized, controlled trial investigating the efficacy and precision of neuronavigation -guided repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute stroke hemiparesis.\n\nThe primary goal is to determine if using neuronavigation to precisely target the unaffected primary motor cortex (M1) improves treatment accuracy, efficiency, and clinical outcomes compared to conventional manual positioning.\n\nThe study will enroll 30 participants with first-ever stroke onset between 2 weeks and 6 months. Participants will be randomized into two parallel groups: the Experimental Group (neuronavigation-guided rTMS) and the Control Group (conventional positioning rTMS). Both groups will receive the same rTMS parameters: 1 Hz stimulation (low-frequency) over the unaffected M1, 1,200 pulses per session, administered for 10 sessions over 2 consecutive weeks.\n\nPrimary outcome measures include the change in the Fugl-Meyer Assessment (FMA) Score for the Upper Extremity and the measurement of coil positioning deviation between sessions. Assessments will be conducted at baseline (T0), post-treatment (T1, Week 3), and one month post-treatment (T2, Week 7). This study is funded in part by a research grant from the Metal Industries Research \\& Development Centre (MIRDC).",[60,61],"Stroke","Hemiparesis After Stroke",[63,64,65],"rTMS","Repetitive Transcranial Magnetic Stimulation","Neuronavigation","NOT_YET_RECRUITING","2025-12-14",{"date":69,"type":70},"2025-12-16","ACTUAL",{"date":72,"type":54},"2026-01-01",{"date":74,"type":54},"2026-12-31",{"name":5,"class":6}]